Clinical trial NCT04286789: Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs
Official title: A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Rheumatoid Arthritis
Lead sponsor: Oryn Therapeutics, LLC
Sponsor class: INDUSTRY
First posted: 2020-02-27
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a randomized, vehicle controlled, double-blind, repeat dose comparative study in patients with rheumatoid arthritis (RA) under management with DMARDs and with persistent disease activity. The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of 6 weekly repeat doses of ORTD-1.


Eligibility criteria: Inclusion Criteria:

* ≥18 years of age or older, males or females.
* Diagnosed rheumatoid arthritis per the American Rheumatism Association 1987 classification criteria of at least 6 months duration.
* Disease activity defined as:

  * erythrocyte sedimentation rate (ESR) \> 24 mm or serum C-reactive protein level ≥ 1.2 times (X) the upper limit of normal (ULN), and
  * DAS28-CRP score ≥ 2.6 and \< 5.1
* Current regimen of DMARDs that may include methotrexate, sulfasalazine, hydroxychloroquine, leflunomide and/or azathioprine, alone or in combination.
* No change in DMARD dose(s) within 4 weeks prior to Screening.
* May be receiving a stable regimen (of at least 4 weeks duration) of concomitant NSAIDs.
* Women of child-bearing potential (WOCBP), defined as a sexually mature woman not surgically sterilized, or not post-menopausal for at least 12 consecutive months. Female subjects must:

  * Not be lactating; not be pregnant upon enrollment.
  * Agree to use highly effective methods of birth control throughout the study. Highly effective methods of contraception include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation by oral, intravaginal, or transdermal administration; progestogen-only hormonal contraception associated with inhibition of ovulation by oral, injectable, or implantable administration; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; partner vasectomy; or total abstinence (only if total abstinence is an established method and lifestyle of the subject).
  * Patients already using hormonal contraception at the time of screening will be eligible but will not initiate hormonal contraception in order to participate in the study.
  * Agree to use highly effective methods of birth control for at least 6 months after the last dose of investigational product.
* Male subjects must refrain from donating sperm or fathering a child during the study.
* Male subjects must use barrier contraception throughout the course of the study.
* Signed and dated informed consent.

Exclusion Criteria:

* Prior therapy with any biologic therapeutic within 3 months prior to enrollment, or in the case of Rituxan (rituximab), this period must be at least 12 months.
* History of or current clinical fibromyalgia or Juvenile Idiopathic Arthritis (JIA).
* Positive diagnosis of SLE.
* Patients with Type 1 or Type 2 Diabetes Mellitus.
* Patients with psoriasis.
* Patients with skin condition(s) or visible abnormalities at or near potential sites of injection (right and left abdomen; right and left thigh) that could mask the assessment of safety.
* Acute illness including current or chronic infections requiring antibiotics, or symptoms of a resolving illness, within 2 weeks prior to study.
* Any investigational drug within 3 months prior to study.
* Patients may not be receiving systemic corticosteroid therapy with the exception of inhaled corticosteroids for the treatment of asthma.
* Any clinically relevant abnormality as assessed by the Investigator, on screening history, physical exam, clinical laboratory, chest X-ray, or ECG, other than values consistent with rheumatoid arthritis, with the exception that liver function tests (ALP, ALT, AST) may be up to 1.5 times (X) the upper limit of normal (ULN).
* Positive serological test for HCV, HBsAg, HBcAg, HIV.
* QuantiFERON-positive patients may be enrolled with documented evidence that they have completed a prescribed course of antituberculous therapy.
* History of cardiovascular disease with New York Heart Association (NYHA) functional class II or greater; or history of stroke, or uncontrolled hypertension.
* History of lymphoproliferative disease, or organ allograft.
* Pregnancy or lactation, or WOCBP not currently using contraceptives or male partners of WOCBP not currently using contraceptives.
* History of cancer (except for in situ cancer, or limited stage cancer of the cervix, head and neck (squamous cell), thyroid, or skin (non-melanomatous) curatively treated with no sign of disease for \> 5 years).
* Any physical or psychological condition that might prevent complete participation in the study, in the view of the investigator.

Primary outcomes:
measure: Safety and Tolerability of ORTD-1 measured by the number of patients with adverse events
timeFrame: 10 weeks
Secondary outcomes:
measure: Immunogenicity by measurement of anti-drug antibodies
timeFrame: Weeks 1, 3, 5, and 10
measure: Serum concentration of ORTD-1 from baseline
timeFrame: 10 weeks
measure: Cmax of ORTD-1
timeFrame: Week 1 through week 6
measure: Tmax of ORTD-1
timeFrame: Week 1 through week 6
Other outcomes:
measure: Change from baseline in disease activity
timeFrame: Weeks 1, 3, 5, and 10
Locations:
city: Los Angeles
country: United States
facility: Keck School of Medicine of USC Division of Rheumatology
state: California
city: Tustin
country: United States
facility: Orange County Research Center
state: California
city: Miami
country: United States
facility: Advanced Pharma CR, LLC
state: Florida
Study officials:
affiliation: Keck School of Medicine of USC Division of Rheumatology
name: William Stohl, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: